Back to Search Start Over

Allograft Versus Bioactive Glass (BG-S53P4) in Pediatric Benign Bone Lesions: A Randomized Clinical Trial.

Authors :
Syvänen J
Serlo W
Jalkanen J
Kohonen I
Raitio A
Nietosvaara Y
Helenius I
Source :
The Journal of bone and joint surgery. American volume [J Bone Joint Surg Am] 2023 May 03; Vol. 105 (9), pp. 659-666. Date of Electronic Publication: 2023 Jan 19.
Publication Year :
2023

Abstract

Background: Benign bone cysts in children have a high risk of recurrence after bone grafting. The optimal treatment and filling material for these lesions are currently unknown.<br />Methods: We compared cyst recurrence after intralesional curettage and filling with allograft versus bioactive glass (BG-S53P4; Bonalive) in a randomized clinical trial. The volume of recurrent cyst at 2-year follow-up was the primary outcome.<br />Results: Of 64 eligible children, 51 (mean age, 11.1 years) were randomized to undergo filling of the cyst using morselized allograft (26) or bioactive glass (25). Twelve (46%) of the children in the allograft group and 10 (40%) in the bioactive glass group developed a recurrence (odds ratio [OR] for bioactive glass = 0.79, 95% confidence interval [CI] = 0.25 to 2.56, p = 0.77). The size of the recurrent cyst did not differ between the allograft group (mean, 3.3 mL; range, 0 to 13.2 mL) and the bioactive glass group (mean, 2.2 mL; range, 0 to 16.6 mL, p = 0.43). After adjusting for the type of lesion (aneurysmal bone cyst versus other), bioactive glass also did not prevent larger (>1 mL) recurrent cysts (adjusted OR = 0.42, 95% CI = 0.13 to 1.40, p = 0.16). The Musculoskeletal Tumor Society score improved significantly (p ≤ 0.013) from preoperatively to the 2-year follow-up in both groups (to 28.7 for bioactive glass and 29.1 for bone graft). Four (15%) of the children in the allograft group and 6 (24%) in the bioactive glass group required a reoperation during the follow-up (OR for bioactive glass = 1.74, 95% CI = 0.43 to 7.09, p = 0.50).<br />Conclusions: Filling with bioactive glass and with allograft in the treatment of benign bone lesions provided comparable results in terms of recurrence and complications.<br />Level of Evidence: Therapeutic Level I . See Instructions for Authors for a complete description of levels of evidence.<br />Competing Interests: Disclosure: The Disclosure of Potential Conflicts of Interest forms are provided with the online version of the article ( http://links.lww.com/JBJS/H409 ).<br /> (Copyright © 2023 by The Journal of Bone and Joint Surgery, Incorporated.)

Details

Language :
English
ISSN :
1535-1386
Volume :
105
Issue :
9
Database :
MEDLINE
Journal :
The Journal of bone and joint surgery. American volume
Publication Type :
Academic Journal
Accession number :
36727973
Full Text :
https://doi.org/10.2106/JBJS.22.00716